The global pharmaceutical dissolution testing services market size is expected to reach USD 1.2 billion by 2030, registering a CAGR of 8.0% from 2023 to 2030. The market is expected to increase primarily as a result of the rising drug development process, increasing technological advancements, rising awareness about the need for high-quality products, and the production of numerous medications for various chronic diseases that require dissolution testing. The COVID-19 pandemic has significantly impacted the global industry. Pharmaceutical firms, biotech firms, and other end-user demands were primarily served during the crisis by developing coronavirus prevention drugs.
Since the end of 2019, these organizations have been actively working toward the development of medications that can be used as a treatment for COVID-19 patients who have only minor symptoms. And these drug developments require dissolution testing at each stage to access safety, stability, and efficacy, thus contributing to industry growth. For the physical assessment of solid dosage forms, such as tablets, capsules, ointments, and creams, dissolution testing is required. The simplest type of testing measures the solubility or rate of dissolving a medication tablet. Dissolution testing can be performed to assess the release rates of a drug material under various situations and to provide details regarding the effectiveness of in vivo performance in Absorption, Distribution, Metabolism, And Excretion (ADME) and bioavailability studies.
Dissolution testing provides information on how quickly or slowly certain drugs are absorbed into various body parts and, subsequently, how much they dissolve after administration. This enables businesses to assess whether a drug will function effectively after it enters a patient's system and whether any negative effects brought on by slower absorption rates would occur. Pharmaceutical dissolution testing requires specialized staff to run the assays and prepare regulatory filings. This factor has greatly increased the demand for professional teams to handle pharmaceutical dissolution testing, which is predicted to have a favorable effect on the industry.
Since the end of 2019, these organizations have been actively working toward the development of medications that can be used as a treatment for COVID-19 patients who have only minor symptoms. And these drug developments require dissolution testing at each stage to access safety, stability, and efficacy, thus contributing to industry growth. For the physical assessment of solid dosage forms, such as tablets, capsules, ointments, and creams, dissolution testing is required. The simplest type of testing measures the solubility or rate of dissolving a medication tablet. Dissolution testing can be performed to assess the release rates of a drug material under various situations and to provide details regarding the effectiveness of in vivo performance in Absorption, Distribution, Metabolism, And Excretion (ADME) and bioavailability studies.
Dissolution testing provides information on how quickly or slowly certain drugs are absorbed into various body parts and, subsequently, how much they dissolve after administration. This enables businesses to assess whether a drug will function effectively after it enters a patient's system and whether any negative effects brought on by slower absorption rates would occur. Pharmaceutical dissolution testing requires specialized staff to run the assays and prepare regulatory filings. This factor has greatly increased the demand for professional teams to handle pharmaceutical dissolution testing, which is predicted to have a favorable effect on the industry.
Pharmaceutical Dissolution Testing Services Market Report Highlights
- The in vitro method segment accounted for the largest revenue share in 2022
- The tablets dosage form segment accounted for the largest share and is anticipated to grow at the fastest CAGR during the forecast period
- Tablets have high physical and chemical stability and the amount of drug delivered to the body can be controlled
- Based on dissolution apparatus, the paddle segment dominated the industry in 2022 as it can cover a range of oral dosage forms
- North America dominated the industry in 2022 owing to rising investments by public firms in research and their state-of-the-art research infrastructure
Table of Contents
Table of Content
Chapter 2 Executive Summary
Chapter 3 Pharmaceutical Dissolution Testing Services Market Variables, Trends, and Scope
Chapter 4 Pharmaceutical Dissolution Testing Services Market: Segment Analysis, By Method, 2018 - 2030 (USD Million)
Chapter 5 Pharmaceutical Dissolution Testing Services Market: Segment Analysis, By Dosage Form, 2018 - 2030 (USD Million)
Chapter 6 Pharmaceutical Dissolution Testing Services Market: Segment Analysis, By Dissolution Apparatus, 2018 - 2030 (USD Million)
Chapter 7 Pharmaceutical Dissolution Testing Services Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)
Chapter 8 Pharmaceutical Dissolution Testing Services Market: Competitive Analysis
List of Tables
List of Figures
Companies Mentioned
- Intertek Group plc
- Avivia Bv
- Almac Group
- Agilent Technologies, Inc.
- Catalent, Inc.
- Thermofisher Scientific Inc.
- Charles River Laboratories
- Cambrex
- Boston Analytical
- Sotax
- Sgs Sa
- Amri
- Pace Analytical Life Sciences
Methodology
LOADING...
